text: Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients - Tabular View - ClinicalTrials.gov
  December 20, 2023 (Final data collection date for primary outcome measure)
  A randomized, open label, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib monotherapy (with steroids if applicable) and the combination of ixazomib and lenalidomide (with steroids if applicable) as maintenance therapy for patients with MM who have achieved at least PR after receiving a bortezomib and lenalidomide (with steroids if applicable)-containing combination frontline therapy.